Salvage thoracoscopic resection after nivolumab for stage IV
暂无分享,去创建一个
A. Yoshizawa | H. Date | M. Hamaji | H. Ozasa
[1] Stephen Broderick,et al. Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.
[2] V. Rusch,et al. Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors. , 2017, The Annals of thoracic surgery.
[3] M. Socinski,et al. First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[4] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[5] Y. Koh,et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. , 2018, Lung cancer.